MPS Pharmaa (ADVIKLA) Q1 FY27's Losses Continue as Factory Awaits FDA License
MPS Pharmaa reported zero revenue and a wider net loss for Q1 FY27 as its manufacturing facility remains shut, pending renewal of its FDA license.
MPS Pharmaa's Q1 FY27 results show a net loss of ₹0.24 crore with zero operating revenue. The company's manufacturing operations are suspended, awaiting renewal of its Drug Manufacturing Licences from the FDA.
For MPS Pharmaa, a pharmaceutical company, the story remains unchanged. Its manufacturing facility has been idle for over a year, and the latest quarter shows the financial toll of that inactivity. The company reported zero revenue from operations and a net loss that has widened from the same period last year.
Revenue & profit
Revenue (₹ Cr.)
Profit (₹ Cr.)
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Period Ended | June 2026 | March 2026 | June 2025 |
| Revenue (₹ Cr.) | 0.00 | 0.04 | 0.00 |
| Profit (₹ Cr.) | -0.24YoY -9.1% | -0.36 | -0.22 |
With no sales, every rupee of expense flows directly to the bottom line. The net loss of ₹0.24 crore for the June quarter was 9.1% wider than the ₹0.22 crore loss a year ago.
Why the Factory Remains Silent
The complete absence of revenue stems from a single, unresolved issue. According to a report by ScanX, the company's Drug Manufacturing Licences with the Food & Drugs Administration (FDA) in Panchkula are pending renewal. Manufacturing operations are suspended until these approvals come through.
Management has expressed confidence in restarting soon, citing discussions with prospective buyers. However, the timeline for regulatory clearance remains the critical unknown.
The Costs of Standing Still
Without revenue, fixed costs become the entire story. ScanX reported that employee benefit expenses of ₹14.36 lakh made up about 60% of the quarter's total expenses of ₹23.80 lakh. The company is burning cash just to maintain a dormant operational shell.
This financial strain is compounded by other pressures. The company has not paid its Annual Listing Fees to the BSE since FY22, leading to trading restrictions. Furthermore, auditors have qualified the accounts over unverified investments and stalled capital work.
A Balance Sheet Under Pressure
The operational hiatus is eroding the company's financial foundation. The debt-to-equity ratio stands at a high 109.8%. Data from MCapital indicates borrowings have risen to ₹7.59 crore as of September 2026, even as equity turned negative.
With no income to service this debt or fund operations, the company's viability hinges entirely on securing its FDA licenses and restarting production. Until then, losses are set to continue.
Key Points
- MPS Pharmaa reported zero revenue and a net loss of ₹0.24 crore for Q1 FY27, with the loss widening year-on-year.
- Manufacturing operations are fully suspended, pending the renewal of Drug Manufacturing Licences from the FDA, Panchkula.
- Fixed employee costs continue to drive losses, while unpaid BSE listing fees have resulted in restricted share trading.
- The company's financial position is weakening, with rising debt and negative equity, as highlighted in subsequent quarterly filings.
Hexa Perspective
The quarter confirms MPS Pharmaa is in a holding pattern with no near-term visibility on a turnaround. The path to profitability is singular: restart the factory. Every week of delay adds to the cash burn and deepens the balance sheet strain.
Investors are left weighing management's optimism against the hard reality of regulatory timelines and mounting liabilities. The stock's 15% decline over the past year reflects the market's assessment of these protracted risks. For now, the story is on pause, awaiting a regulatory green light.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
